每年两次depemokimab治疗2型嗜酸性表型哮喘的2年长期安全性和有效性:SWIFT-1/SWIFT-2与AGILE开放标签扩展整合分析
基于3a期SWIFT-1/SWIFT-2及AGILE开放标签扩展(OLE)的104周整合分析,评估每26周皮下注射depemokimab 100 mg在2型嗜酸性哮喘患者中的长期安全性和有效性。AGILE OLE纳入629例患者,不良事件发生率在depemokimab-depemokimab组为71%、安慰剂-depemokimab组为70%,严重不良事件均为9%,无治疗相关或致死性严重不良事件。
要点
- 每26周皮下注射depemokimab 100 mg在2年内心血管事件和严重不良事件发生率低,耐受性良好。
- SGRQ总分、ACQ-5评分和FEV1的改善在2年内维持,安慰剂组换用depemokimab后也见改善。
核心结论
- 每26周皮下注射depemokimab 100 mg在2年SWIFT和AGILE期间耐受良好,并显示持续疗效,支持其长期治疗获益和安全性。
研究设计与样本
- SWIFT-1和SWIFT-2为双盲、安慰剂对照3a期研究,患者随机(2:1)接受皮下depemokimab 100 mg或安慰剂每26周一次,共52周。
- AGILE为单臂52周开放标签扩展研究,在14个国家156个中心开展,纳入完成SWIFT-1或SWIFT-2的患者。
- AGILE OLE纳入629例患者(depemokimab-depemokimab组419例,安慰剂-depemokimab组210例)。
- 事后分析评估104周SWIFT和AGILE整合期间的安全性和有效性。
主要发现
- AGILE OLE 52周期间,depemokimab-depemokimab组不良事件发生297/419(71%),安慰剂-depemokimab组146/210(70%)。
- 严重不良事件少见:depemokimab-depemokimab组37/419(9%),安慰剂-depemokimab组19/210(9%),无治疗相关或致死性严重不良事件。
- SGRQ总分、ACQ-5评分和FEV1的改善维持2年;安慰剂-depemokimab组换用depemokimab后临床结局改善。
关键数值与推荐
- 纳入标准:年龄≥12岁,2型炎症哮喘伴嗜酸性表型(筛查时≥150 cells/μL或既往12个月内≥300 cells/μL),且过去12个月内至少2次急性发作 despite 中剂量或高剂量吸入糖皮质激素。
- 干预:皮下depemokimab 100 mg每26周一次,联合标准治疗。
- 主要终点:AGILE OLE 52周期间不良事件和严重不良事件发生率,以及抗药物抗体和中和抗体免疫原性。
临床怎么用
- 对于2型嗜酸性表型哮喘患者,每26周皮下注射depemokimab 100 mg可作为长期维持治疗选择,需结合标准治疗。
- 长期使用需监测不良事件和免疫原性,尽管严重不良事件少见且无治疗相关严重事件。
局限性
- AGILE为单臂开放标签扩展研究,缺乏平行对照组。
- 事后整合分析可能受混杂因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Depemokimab is the first ultra-long-acting biologic, with enhanced interleukin-5 binding affinity, high potency, and extended half-life, enabling twice-yearly dosing. The double-blind, placebo-controlled, phase 3a SWIFT-1 and SWIFT-2 studies demonstrated depemokimab efficacy and safety over 52 weeks in patients with asthma with type 2 inflammation and an eosinophilic phenotype. Here, we present long-term safety and efficacy outcomes over the 52-week, phase 3a open-label extension (OLE) of SWIFT-1 and SWIFT-2 (AGILE) alongside an integrated post-hoc analysis of the 104-week SWIFT and AGILE period. METHODS: In SWIFT-1 and SWIFT-2, patients (aged ≥12 years) with asthma with type 2 inflammation, an eosinophilic phenotype (≥150 cells/μL at screening or ≥300 cells/μL during the previous 12 months), and a history of at least two exacerbations in the previous 12 months despite receiving medium-dose or high-dose inhaled corticosteroids were randomly assigned (2:1) to subcutaneous depemokimab 100 mg or placebo every 26 weeks in addition to standard of care for 52 weeks. Patients who completed SWIFT-1 or SWIFT-2 could join the single-arm, 52-week AGILE OLE study, conducted at 156 centres across 14 countries. Patients continued depemokimab (depemokimab-depemokimab group) or switched to depemokimab from placebo (placebo-depemokimab group). The primary endpoints for the 52-week AGILE OLE period were the incidence of adverse events and serious adverse events, and immunogenicity as measured by the presence of anti-drug antibodies and neutralising antibodies. Secondary efficacy outcomes, including exacerbation rate, St George's Respiratory Questionnaire (SGRQ) total score, Asthma Control Questionnaire-5 (ACQ-5) score, and pre-bronchodilator forced expiratory volume in 1 second (FEV1), were also assessed. Additional post-hoc analyses were carried out to assess safety and efficacy over the 104-week integrated SWIFT and AGILE analysis period. AGILE OLE is registered with ClinicalTrials.gov, NCT05243680. The SWIFT-1 and SWIFT-2 trials are registered with ClinicalTrials.gov, NCT04719832 and NCT04718103. FINDINGS: Between March 1, 2022, and May 19, 2025, 629 patients were included in the AGILE OLE study (419 patients in the depemokimab-depemokimab group and 210 patients in the placebo-depemokimab group). During the 52-week AGILE OLE period, adverse events occurred in 297 (71%) of 419 patients in the depemokimab-depemokimab group and 146 (70%) of 210 patients in the placebo-depemokimab group; serious adverse events were infrequent (37 [9%] of 419 in the depemokimab-depemokimab group and 19 [9%] of 210 in the placebo-depemokimab group), with no treatment-related or fatal serious adverse events reported. In the depemokimab-depemokimab group, the reduced annualised exacerbation rate was sustained over 2 years (0·51 [95% CI 0·43-0·61] in the 52-week SWIFT-1 and SWIFT-2 period and 0·56 [0·47-0·66] in the AGILE OLE). Improvements in SGRQ total score, ACQ-5 score, and FEV1 were maintained over 2 years. In the placebo-depemokimab group, improvements in clinical outcomes were observed after the switch to depemokimab during the AGILE OLE. INTERPRETATION: Twice-yearly depemokimab was well tolerated and demonstrated sustained efficacy over the 2-year SWIFT and AGILE period, supporting its long-term therapeutic benefit and safety profile. FUNDING: GSK.
引用
- Wechsler ME, Pfeffer PE, Bernstein DI, et al. Long-term safety and efficacy of twice-yearly depemokimab in type 2 asthma with an eosinophilic phenotype: 2-year integrated analysis of the phase 3a SWIFT-1 and SWIFT-2 studies and AGILE open-label extension. Lancet Respir Med. 2026. PMID: 42956801. doi:10.1016/S2213-2600(26)00259-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。